140 related articles for article (PubMed ID: 34391480)
1. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity.
Bianzano S; Heise T; Jungnik A; Schepers C; Schölch C; Gräfe-Mody U
Clin Diabetes Endocrinol; 2021 Aug; 7(1):16. PubMed ID: 34391480
[TBL] [Abstract][Full Text] [Related]
2. Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days.
Bianzano S; Schepers C; Wolff M; Heise T; Plum-Moerschel L
Exp Clin Endocrinol Diabetes; 2022 Dec; 130(12):773-782. PubMed ID: 36343645
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Bianzano S; Nordaby M; Plum-Mörschel L; Peil B; Heise T
Diabetes Obes Metab; 2023 Mar; 25(3):832-843. PubMed ID: 36478142
[TBL] [Abstract][Full Text] [Related]
5. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).
Webster SP; McBride A; Binnie M; Sooy K; Seckl JR; Andrew R; Pallin TD; Hunt HJ; Perrior TR; Ruffles VS; Ketelbey JW; Boyd A; Walker BR
Br J Pharmacol; 2017 Mar; 174(5):396-408. PubMed ID: 28012176
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers.
Hüttner S; Graefe-Mody EU; Withopf B; Ring A; Dugi KA
J Clin Pharmacol; 2008 Oct; 48(10):1171-8. PubMed ID: 18812608
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor.
Gibbs JP; Emery MG; McCaffery I; Smith B; Gibbs MA; Akrami A; Rossi J; Paweletz K; Gastonguay MR; Bautista E; Wang M; Perfetti R; Daniels O
J Clin Pharmacol; 2011 Jun; 51(6):830-41. PubMed ID: 20663992
[TBL] [Abstract][Full Text] [Related]
8. Continuous inhibition of 11β-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice.
Morentin Gutierrez P; Gyte A; deSchoolmeester J; Ceuppens P; Swales J; Stacey C; Eriksson JW; Sjöstrand M; Nilsson C; Leighton B
Br J Pharmacol; 2015 Oct; 172(20):4806-16. PubMed ID: 26218540
[TBL] [Abstract][Full Text] [Related]
9. Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.
Ajjan RA; Hensor EMA; Del Galdo F; Shams K; Abbas A; Fairclough RJ; Webber L; Pegg L; Freeman A; Taylor AE; Arlt W; Morgan AW; Tahrani AA; Stewart PM; Russell DA; Tiganescu A
Eur J Endocrinol; 2022 Feb; 186(4):441-455. PubMed ID: 35113805
[TBL] [Abstract][Full Text] [Related]
10. First in human randomised trial of J2H-1702: A novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor for non-alcoholic steatohepatitis treatment.
Kim Y; Lee SR; Lee SW
Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1132-1142. PubMed ID: 37743843
[TBL] [Abstract][Full Text] [Related]
11. Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.
Wiegand S; Richardt A; Remer T; Wudy SA; Tomlinson JW; Hughes B; Grüters A; Stewart PM; Strasburger CJ; Quinkler M
Eur J Endocrinol; 2007 Sep; 157(3):319-24. PubMed ID: 17766714
[TBL] [Abstract][Full Text] [Related]
12. Association studies between microsatellite markers within the gene encoding human 11beta-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism.
Draper N; Echwald SM; Lavery GG; Walker EA; Fraser R; Davies E; Sørensen TI; Astrup A; Adamski J; Hewison M; Connell JM; Pedersen O; Stewart PM
J Clin Endocrinol Metab; 2002 Nov; 87(11):4984-90. PubMed ID: 12414862
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
14. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
[TBL] [Abstract][Full Text] [Related]
15. Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor.
Courtney R; Stewart PM; Toh M; Ndongo MN; Calle RA; Hirshberg B
J Clin Endocrinol Metab; 2008 Feb; 93(2):550-6. PubMed ID: 17986636
[TBL] [Abstract][Full Text] [Related]
16. Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT).
Woods CP; Corrigan M; Gathercole L; Taylor A; Hughes B; Gaoatswe G; Manolopoulos K; Hogan AE; O'Connell J; Stewart PM; Tomlinson JW; O'Shea D; Sherlock M
J Clin Endocrinol Metab; 2015 Apr; 100(4):1434-44. PubMed ID: 25603461
[TBL] [Abstract][Full Text] [Related]
17. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.
Wright DH; Stone JA; Crumley TM; Wenning L; Zheng W; Yan K; Yang AY; Sun L; Cilissen C; Ramael S; Hermanowski-Vosatka A; Langdon RB; Gottesdiener KM; Wagner JA; Lai E
Br J Clin Pharmacol; 2013 Dec; 76(6):917-31. PubMed ID: 23594227
[TBL] [Abstract][Full Text] [Related]
19. Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.
Moschetti V; Schlecker C; Wind S; Goetz S; Schmitt H; Schultz A; Liesenfeld KH; Wunderlich G; Desch M
Clin Drug Investig; 2018 Aug; 38(8):737-750. PubMed ID: 29846887
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
Rauz S; Cheung CM; Wood PJ; Coca-Prados M; Walker EA; Murray PI; Stewart PM
QJM; 2003 Jul; 96(7):481-90. PubMed ID: 12881590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
